- Novimmune to receive $115.86M, out of $518.76M and has already received $402.9M under its exclusive license agreement signed with Sobi in 2018. Sobi to get IP & patent rights, associated employees of emapalumab with an option for shared financial rights to NI-1701 & NI-1801.
- Sobi has also received the US FDA’s PR voucher for emapalumab with an expected completion of the acquisition in Q3’19 and plans to establish a center of excellence in Sweden and Switzerland for hematology & immunology respectively
- Emapalumab is a mAb, binding to & neutralizing interferon gamma (IFNγ), indicated for HLH in pediatric & adults. In Jul’18, Novimmune grants exclusive global rights of emapalumab to Sobi which is now replaced with the acquisition